AstraZeneca plc (AZN) Position Reduced by First Republic Investment Management Inc.

First Republic Investment Management Inc. decreased its position in shares of AstraZeneca plc (NYSE:AZN) by 22.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,916 shares of the company’s stock after selling 13,850 shares during the period. First Republic Investment Management Inc.’s holdings in AstraZeneca were worth $1,657,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Dorsey & Whitney Trust CO LLC raised its holdings in AstraZeneca by 0.7% during the second quarter. Dorsey & Whitney Trust CO LLC now owns 13,315 shares of the company’s stock worth $454,000 after purchasing an additional 94 shares in the last quarter. Financial Counselors Inc. raised its stake in AstraZeneca by 2.7% during the 2nd quarter. Financial Counselors Inc. now owns 6,871 shares of the company’s stock valued at $234,000 after purchasing an additional 182 shares during the period. FTB Advisors Inc. raised its stake in AstraZeneca by 3.2% during the 2nd quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock valued at $197,000 after purchasing an additional 200 shares during the period. Pinnacle Financial Partners Inc. raised its stake in AstraZeneca by 2.5% during the 2nd quarter. Pinnacle Financial Partners Inc. now owns 9,233 shares of the company’s stock valued at $314,000 after purchasing an additional 229 shares during the period. Finally, Beacon Investment Advisory Services Inc. raised its stake in AstraZeneca by 4.9% during the 2nd quarter. Beacon Investment Advisory Services Inc. now owns 7,944 shares of the company’s stock valued at $271,000 after purchasing an additional 373 shares during the period. 14.75% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have issued reports on AZN. Liberum Capital downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. BNP Paribas upgraded shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. BMO Capital Markets restated a “buy” rating and set a $38.00 price target on shares of AstraZeneca in a report on Tuesday, November 7th. Citigroup upgraded shares of AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. Finally, Sanford C. Bernstein upgraded shares of AstraZeneca from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $30.00 to $39.00 in a report on Friday, September 22nd. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. AstraZeneca currently has a consensus rating of “Hold” and an average price target of $34.20.

Shares of AstraZeneca plc (NYSE AZN) opened at $33.42 on Wednesday. The stock has a market cap of $83,858.58, a price-to-earnings ratio of 7.90, a P/E/G ratio of 3.01 and a beta of 0.72. AstraZeneca plc has a fifty-two week low of $26.51 and a fifty-two week high of $35.60. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.55. The firm had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. AstraZeneca’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.32 earnings per share. analysts anticipate that AstraZeneca plc will post 1.87 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (AZN) Position Reduced by First Republic Investment Management Inc.” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/13/astrazeneca-plc-azn-position-reduced-by-first-republic-investment-management-inc.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply